US/UK/Canada

Share

Pick a time period -
Tags ( Active)

CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78

In the second quarter of 2025, CHOSA Oncology AB (publ) ("Chosa" or the "Company") issued 7,951,740 warrants of series TO2 in connection with an issue of units.The exercise period commences today, 1 July 2026, and the exercise price amounts to SEK 0.78 per share.If fully exercised, the TO2 warrants will provide CHOSA Oncology with approximately SEK 6.2 million before transaction costs. The proceeds are intended to further accelerate:         CLIA laboratory certification will enable the transition from Research Use Only (RUO) status to clinical commercialization for patient testing

CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP

23 June 2026 – CHOSA Oncology AB ("CHOSA" or the "Company") today announces that it has established a business presence in Boston, Massachusetts, marking an important strategic step in the Company's US commercialization for Platin-DRP®. The decision reflects CHOSA's commitment to building a long-term presence in the United States as it advances the market launch of its proprietary biomarker platform. The establishment of a US presence reflects CHOSA's strategic focus on the United States as a key commercial market for Platin-DRP® and provides a platform for expanding relationships with

CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. 01 June 2026 - CHOSA Oncology AB (“CHOSA” or the “Company”) in cooperation with and AIDA Oncology ApS (“AIDA”) today jointly announces publication of a new ASCO 2026 abstract presenting data from the I-SPY2 study showing that combined use of CHOSA’s platinum Drug Response Predictor - Platin-DRP® from CHOSA - and a taxane docetaxel response predictor Oncotect from AIDA, through a collaboration with AIDA Oncology, identified breast

CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. 01 June 2026 - CHOSA Oncology AB (“CHOSA” or the “Company”) today announces publication of a ASCO 2026 abstract presenting additional data demonstrating the ability of the Company’s Platin-DRP® biomarker to predict OS in advanced non-small cell lung cancer (NSCLC) using the NanoString technology.The abstract reports significant associations between Platin-DRP® scores and overall survival (OS) in platinum-treated NSCLC patients

Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.Today, on 27 May 2026, the annual general meeting was held in Chosa Oncology AB. A summary of the adopted resolutions follows below.   Resolution on adoption of accounts and distribution of the company’s profit The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting also

CHOSA Oncology publishes the Annual and Consolidated Financial Statements for the financial year 2025

6 May 2026 – CHOSA Oncology AB hereby announces that the Annual Report for 2025 is available for download on CHOSA’s website, https://www.chosaoncology.se. The Annual Report is also attached as a PDF to this press release.For more information please contact: Peter Buhl Jensen, CEO peter@chosa.bio + 45 21 60 89 22   About CHOSA Oncology ABCHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression–based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes

CHOSA Oncology partners with Mount Sinai, New York to test biomarker guiding platin-immunotherapy in lung cancer

27th of April 2026 CHOSA Oncology AB (“CHOSA” or the “Company”) today announces a new collaboration between CHOSA Oncology and the Icahn School of Medicine at Mount Sinai, New York, USA that aims to answer a critical question in lung cancer treatment: which patients actually benefit from platin combined with immunotherapy?A large and growing clinical need Lung cancer remains the leading cause of cancer-related death worldwide, with around 2 million new cases annually, the majority being NSCLC. Approximately 1 million patients receive platinum-based chemotherapy each year, and an

Notice of annual general meeting in Chosa Oncology AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of Chosa Oncology AB, Reg. No. 559037-2271, are invited to attend the annual general meeting to be held on Wednesday 27 May 2026 at 10.00 a.m. at Medicon Village, in the building Inspira, conference room Arvid, Scheelevägen 4, Lund, Sweden.Right to participate and notification Shareholders wishing to participate in the annual general meeting must: · partly be listed in the company’s share register kept

CHOSA to present new Platin-DRP® data at ASCO 2026

24th April 2026 - CHOSA Oncology AB (“CHOSA” or the “Company”) today announces that new data on its Drug Response Predictor, Platin-DRP®, has been selected for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2026, taking place May 29 - June 2, 2026, at McCormick Place, Chicago, Illinois, USA.The Company will present two scientific abstracts highlighting the potential clinical utility of Platin-DRP® across multiple cancer settings and technologies: · mRNA-based profile to predict platinum sensitivity in NSCLC assessed by NanoString – a

CHOSA presents positive data on Platin-DRP® predicting overall survival in advanced NSCLC at the European Lung Cancer Congress 2026

26 March 2026 - CHOSA Oncology AB (“CHOSA” or the “Company”) today announced presentation of positive data from its collaboration with international lung cancer experts in the European Thoracic Oncology Platform (ETOP IBCSG Partners Foundation) and the European Organisation for Research and Treatment of Cancer (EORTC). The results were presented today at the European Lung Cancer Congress (ELCC) 2026 in Copenhagen.The project evaluates CHOSA’s Platin-DRP® in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy in the Phase III SPLENDOUR trial.

CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress

19th March 2026 CHOSA Oncology today announced that data on its Platin-DRP biomarker in advanced non-small cell lung cancer (NSCLC) will be presented at ELCC 2026 - European Lung Cancer Congress - on Thursday March 26. The conference takes place 25-28 March 2026 in Copenhagen, Denmark.The presentation will present results from a translational analysis based on patients from the ETOP/EORTC Phase III SPLENDOUR trial. The study was conducted as a collaboration between CHOSA and ETOP/EORTC and evaluates the association between CHOSA’s Platin-DRP score and clinical outcomes in platinum-treated

Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. 23 th January 2026, CHOSA Oncology AB announced that its international patent application has been published under the Patent Cooperation Treaty (PCT), covering CHOSA’s predictive technology designed to identify cancer patients likely to benefit from treatment combining platinum-based chemotherapy with PD-(L)1 immunotherapy.The patent application describes a method that uses biological information derived from a patient’s tumour

CHOSA Oncology AB resolves on a directed issue of units of initially approximately SEK 7.3 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.This English-language version is a translation of the original Swedish stock exchange release. In the event of any discrepancies between the English translation and the Swedish original, the Swedish version shall prevail. The

CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. 11th December 2025, CHOSA Oncology AB announced new positive data read-out supporting the clinical relevance of its Platin-DRP® biomarker, now also on the NanoString platform. Using NanoString’s transcriptomic platform, CHOSA has demonstrated that the NanoString-based Platin-DRP® with statistical significance can predict overall survival in non-small cell lung cancer (NSCLC) patients treated with platinum chemotherapy.These

CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. 10 November 2025, CHOSA Oncology AB announced - While immune checkpoint inhibitors (PD-1/PD-L1 drugs) have transformed the treatment landscape in advanced non-small cell lung cancer (NSCLC), a new meta-analysis and updated treatment guidelines make it clear that these regimens continue to rely on platinum chemotherapy - specifically cisplatin and carboplatin - as their foundation.In recent years, immunotherapy has often been

CHOSA’s presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.  20th, October 2025, CHOSA Oncology AB announced its new clinical data presented at the ESMO 2025 Annual Congress Poster session today in Berlin, demonstrating the ability of its cisplatin-derived Drug Response Predictor (Platin-DRP®) to predict clinical benefit from carboplatin in patients with metastatic breast cancer (MBC). The title of was: “Validation of a cisplatin response predictor in carboplatin-treated metastatic breast

CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.  7 October 2025 – As part of its international business development efforts, CHOSA is exploring opportunities in China - a market that today accounts for more than 50 percent of all new immunotherapy developments. This aligns directly with CHOSA’s mission: to improve treatment outcomes in lung and breast cancer through its platin-response prediction technology Platin-DRP®. Following a series of regional competitions in China and

CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Findings to be presented at upcoming scientific conference and submitted for publication30, September 2025 – CHOSA Today announced positive results from its collaboration with international lung cancer experts in the European Thoracic Oncology Platform (ETOP IBCSG Partners Foundation) and the European Organisation for Research and Treatment of Cancer (EORTC). The project evaluates CHOSA’s Drug Response Predictor (Platin-DRP®) in

CHOSA’s presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. 8th, August 2025, – CHOSA announces that an abstract titled “Validation of a cisplatin response predictor in carboplatin-treated metastatic breast cancer patients” has been accepted for a Poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, 17–21 October 2025. Further details will be disclosed once available.Cisplatin and carboplatin are closely related platinum-based

Chosa Oncology’s warrants of series TO 2 to be admitted to trading

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.Chosa Oncology AB ("Chosa" or the "Company") announces that its warrants of series TO 2 will be admitted to trading on Spotlight Stock Market as of August 5, 2025, under the ticker “CHOSA TO 2” with ISIN code SE0025186745.

Chosa Oncology announces the last day of trading in BTU

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.Chosa Oncology AB ("Chosa" or the "Company") announces that the rights issue of units that was announced on June 2, 2025 (the “Rights Issue”) has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket)

CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.July 01, 2025 – CHOSA announces that the timeline from the collaboration with ETOP on validating the platin-DRP on data from the Splendour study will be pushed into Q3 2025. Late in the biopsy gathering process we have been given the option to look at additional study biopsies. A positive opportunity for CHOSA that we have decided to accept. This will result in c. 110 biopsies living up to CHOSA’s quality criteria. The expected

Chosa Oncology announces outcome in rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.On June 2, 2025, the Board of Directors of Chosa Oncology AB ("Chosa" or the "Company”) resolved on a directed issue of shares and warrants series TO 2 of initially approximately SEK 3.4 million (the “Directed Issue”), and on a

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe